Once Daily Given Alfuzosin in the Treatment of BPH
Once Daily Given Alfuzosin in the Treatment of BPH
Collection of the data on the safety and efficacy of the once daily administration of the
 alfuzosin preparation /Alfetim Uno® l0 mg/ at patients with lower urinary tract
 symptoms/complaints rendering possible the presence of benign prostatic hyperplasia, in the
 course of everyday practice
Inclusion Criteria:

 -  Sexually active male patient with lower urinary tract symptoms indicative of severe
 BPH, at whom disturbances of urinary retention and urination are present

 Exclusion Criteria:

 -  Necessity of surgical intervention immediately or within 12 months because of BPH

 -  The patient has earlier /within 6 months/ obtained treatment because of BPH

 -  The patient did not improve on earlier alpha-1 blocker treatment

 -  Known hypersensitivity to alfuzosin

 -  Orthostatic hypotension in the history

 -  Concomitant application with another alpha-1 blocker

 -  Hepatic insufficiency /AST, ALT 3 fold of the upper limit of the normal value/

 -  Severe renal insufficiency /se creatinine greater than or equal to 150 umol/l/

 -  Intestinal obstruction /because of the castor oil content of the drug/

 -  Tumorous disease

 -  Severe, life threatening state

 The above information is not intended to contain all considerations relevant to a patient's
 potential participation in a clinical trial.